Skip to main content

Trodelvy Disease Interactions

There are 2 disease interactions with Trodelvy (sacituzumab govitecan).

Moderate

Sacituzumab govitecan (applies to Trodelvy) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The safety of sacituzumab govitecan has not been established in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN]) or severe (total bilirubin greater than 3 x ULN) liver dysfunction; it has not been tested in patients with AST or ALT greater than 3 x ULN without liver metastases, or AST or ALT greater than 5 x ULN with liver metastases. No recommendations can be made for the starting dosage; caution is advised in patients with moderate or severe liver dysfunction. No adjustment to the starting dosage is needed in patients with mild liver dysfunction.

References

  1. (2020) "Product Information. Trodelvy (sacituzumab govitecan)." Immunomedics
  2. (2023) "Product Information. Trodelvy (sacituzumab govitecan)." Immunomedics, SUPPL-35
Moderate

Sacituzumab govitecan (applies to Trodelvy) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

There are no data on the pharmacokinetics of sacituzumab govitecan in patients with severe renal dysfunction (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min); caution is recommended in these patients.

References

  1. (2023) "Product Information. Trodelvy (sacituzumab govitecan)." Immunomedics, SUPPL-35

Trodelvy drug interactions

There are 112 drug interactions with Trodelvy (sacituzumab govitecan).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer